One review of lung cancer management in South Africa noted that for private sector patients with EGFR mutations, only erlotinib is available for first line use, osimertinib is available in the second line setting and crizotinib is the only drug available for ALK positive patients [76]. Here, ALK is linked to lung carcinoma.